Your search for Warfarin returned 31 results

An alternative approach to treating potentially fatal blood clots may be more effective, cheaper, and may allow patients to go home the same day, researchers from the Indiana University School of Medicine reported.

In patients with a first episode of pulmonary embolism who took six months of anticoagulants, another 18 months of treatment with warfarin reduced the risk of blood clots and major bleeding, though the benefit was not maintained after discontinuing anticoagulation therapy, a study has shown.

Patients with atrial fibrillation who discontinued blood thinners prior to elective surgery did not have an increased risk of developing blood clots and had less risk of major bleeding compared to patients who were given a ‘bridge” therapy, scientists from the Duke Medicine reported.

Findings from a recent study suggests that clinical and genetic factors affecting warfarin dose requirements differ by race.

Appropriate patient selection and pharmacist-led monitoring were linked to greater adherence to dabigatran among patients with atrial fibrillation at Veterans Health Administration sites, according to a recent study published in JAMA.

Patients treated with Xarelto (rivaroxaban; Janssen) for deep vein thrombosis (DVT) had less frequent hospital admissions than those treated with standard low molecular weight heparin (LMWH) and warfarin, according to study data presented at the Hospital Medicine 2015 Congress.

The MIND diet may significantly reduce the risk of developing Alzheimer’s disease even if the diet is not rigorously followed, an article has shown.

Boston Scientific announced that the Food and Drug Administration (FDA) has approved WATCHMAN Left Atrial Appendage Closure Device to reduce the risk of stroke in high-risk patients with non-valvular atrial fibrillation who are looking for an alternative to long-term warfarin therapy.

Results from an ongoing 5-year post-marketing study evaluating the safety of Xarelto (rivaroxaban; Janssen) show that rates and patterns of major bleeding in clinical practice are overall consistent with those seen in Phase 3 clinical trials used to approve the medicine.

Daiichi Sankyo announced that the FDA has approved Savaysa (edoxaban) tablets to reduce the risk of stroke and systemic embolism (SE) in patients with non-valvular atrial fibrillation (NVAF), and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of initial therapy with a parenteral anticoagulant.